Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escalated Permethrin Therapy for Scabies (ETSKABI)
NCT04814511Phase 3Unknown
- Sponsor
- InfectoPharm
- Start
- Jun 2021
- Primary completion
- Dec 2022
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of permethrin in scabies (4 arms), sponsored by InfectoPharm. Primary endpoint: Clinical Efficacy of Standard Therapy at Day 28. Status: unknown.
02
Drugs
permethrin
03
Conditions
scabies
Beyond the preview
Go deeper on NCT04814511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04814511.